Literature DB >> 28063071

Interstitial lung disease in systemic sclerosis: current and future treatment.

Roberto Giacomelli1, Vasiliki Liakouli2, Onorina Berardicurti2, Piero Ruscitti2, Paola Di Benedetto2, Francesco Carubbi2, Giuliana Guggino3, Salvatore Di Bartolomeo2, Francesco Ciccia3, Giovanni Triolo3, Paola Cipriani2.   

Abstract

Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SSc-ILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis, diagnosis, prognosis, survival and finally current and future treatment options in SSc-ILD.

Entities:  

Keywords:  Fibrosis; Interstitial lung disease; Scleroderma; Systemic sclerosis; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28063071     DOI: 10.1007/s00296-016-3636-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  95 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

Authors:  J R Seibold; C P Denton; D E Furst; L Guillevin; L J Rubin; A Wells; M Matucci Cerinic; G Riemekasten; P Emery; H Chadha-Boreham; P Charef; S Roux; C M Black
Journal:  Arthritis Rheum       Date:  2010-07

Review 3.  Survival after lung transplantation in systemic sclerosis. A systematic review.

Authors:  Irfan Y Khan; Lianne G Singer; Marc de Perrot; John T Granton; Shaf Keshavjee; Cathy Chau; Amie Kron; Sindhu R Johnson
Journal:  Respir Med       Date:  2013-09-26       Impact factor: 3.415

Review 4.  Mortality and survival in systemic sclerosis: systematic review and meta-analysis.

Authors:  Manuel Rubio-Rivas; Cristina Royo; Carmen Pilar Simeón; Xavier Corbella; Vicent Fonollosa
Journal:  Semin Arthritis Rheum       Date:  2014-05-14       Impact factor: 5.532

5.  Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1.

Authors:  Raksha Jain; Philip W Shaul; Zea Borok; Brigham C Willis
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-22       Impact factor: 6.914

6.  Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease.

Authors:  D J Abraham; R Vancheeswaran; M R Dashwood; V S Rajkumar; P Pantelides; S W Xu; R M du Bois; C M Black
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

7.  Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.

Authors:  Lisa M Rice; Cristina M Padilla; Sarah R McLaughlin; Allison Mathes; Jessica Ziemek; Salma Goummih; Sashidhar Nakerakanti; Michael York; Giuseppina Farina; Michael L Whitfield; Robert F Spiera; Romy B Christmann; Jessica K Gordon; Janice Weinberg; Robert W Simms; Robert Lafyatis
Journal:  J Clin Invest       Date:  2015-06-22       Impact factor: 14.808

8.  Cigarette smoking in patients with systemic sclerosis.

Authors:  Marie Hudson; Ernest Lo; Ying Lu; Daniel Hercz; Murray Baron; Russell Steele
Journal:  Arthritis Rheum       Date:  2011-01

Review 9.  Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review.

Authors:  Tiffany A Winstone; Deborah Assayag; Pearce G Wilcox; James V Dunne; Cameron J Hague; Jonathon Leipsic; Harold R Collard; Christopher J Ryerson
Journal:  Chest       Date:  2014-08       Impact factor: 9.410

10.  Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.

Authors:  Alice Bérezné; Brigitte Ranque; Dominique Valeyre; Michel Brauner; Yannick Allanore; David Launay; Véronique Le Guern; Jean-Emmanuel Kahn; Louis-Jean Couderc; Joël Constans; Pascal Cohen; Alfred Mahr; Christian Pagnoux; Eric Hachulla; André Kahan; Jean Cabane; Loïc Guillevin; Luc Mouthon
Journal:  J Rheumatol       Date:  2008-05-01       Impact factor: 4.666

View more
  31 in total

1.  Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis.

Authors:  Travis B Lear; Karina C Lockwood; Mads Larsen; Ferhan Tuncer; Jason R Kennerdell; Christina Morse; Eleanor Valenzi; Tracy Tabib; Michael J Jurczak; Daniel J Kass; John W Evankovich; Toren Finkel; Robert Lafyatis; Yuan Liu; Bill B Chen
Journal:  J Biol Chem       Date:  2020-02-17       Impact factor: 5.157

2.  Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.

Authors:  David Roofeh; Oliver Distler; Yannick Allanore; Christopher P Denton; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2020-03-05

3.  The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center.

Authors:  Luwei Yang; Qian Wang; Yong Hou; Jiuliang Zhao; Mengtao Li; Dong Xu; Xiaofeng Zeng
Journal:  Clin Rheumatol       Date:  2019-11-12       Impact factor: 2.980

Review 4.  [Treatment of systemic sclerosis-associated interstitial lung disease].

Authors:  A Prasse; F Bonella; U Müller-Ladner; T Witte; N Hunzelmann; J Distler
Journal:  Z Rheumatol       Date:  2020-04       Impact factor: 1.372

5.  Role of STAT3 in skin fibrosis and transforming growth factor beta signalling.

Authors:  Mesias Pedroza; Sarah To; Shervin Assassi; Minghua Wu; David Tweardy; Sandeep K Agarwal
Journal:  Rheumatology (Oxford)       Date:  2018-10-01       Impact factor: 7.580

6.  Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease.

Authors:  Eunju Jung; Chang-Hee Suh; Hyoun-Ah Kim; Ju-Yang Jung
Journal:  Arch Rheumatol       Date:  2018-01-15       Impact factor: 1.472

7.  Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis.

Authors:  Xiang Tong; Yao Ma; Tao Liu; Zhenzhen Li; Sitong Liu; Guihui Wu; Hong Fan
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

8.  Modulation of microRNome by Human Cytomegalovirus and Human Herpesvirus 6 Infection in Human Dermal Fibroblasts: Possible Significance in the Induction of Fibrosis in Systemic Sclerosis.

Authors:  Irene Soffritti; Maria D'Accolti; Gloria Ravegnini; Maria-Cristina Arcangeletti; Clara Maccari; Flora De Conto; Adriana Calderaro; Elisabetta Caselli
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

9.  Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants.

Authors:  Nina M van Leeuwen; Jacopo Ciaffi; Sophie I E Liem; Tom W J Huizinga; Jeska K de Vries-Bouwstra
Journal:  Rheumatology (Oxford)       Date:  2021-08-02       Impact factor: 7.580

Review 10.  Endothelial-to-mesenchymal transition in systemic sclerosis.

Authors:  P Cipriani; R Giacomelli; P Di Benedetto; P Ruscitti; O Berardicurti; M Vomero; L Navarini; V Dolo
Journal:  Clin Exp Immunol       Date:  2021-04-18       Impact factor: 5.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.